Merck, Keytruda and colorectal cancer
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
After facing colorectal cancer for nearly eight years, Mandy Wilk got a double-lung transplant in June at Northwestern. She ...
For the past year, Kulkarni had noticed some gastrointestinal issues, but he suspected it was nothing more than irritable ...
Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction of recurrence in stage ...
Research has revealed how disruption of the circadian clock, the body's internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and ...
Surgeons at Chicago's Northwestern Medicine gave Mandy Wilk, a cancer patient, a first-of-its-kind double lung transplant.
as a treatment for a type of colon cancer. The fixed dose combination did not demonstrate an improvement in OS compared to standard of care in patients with previously treated PD-L1 positive ...
IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...
Colon cancer is increasingly affecting the younger population. It's essential to be informed about the risk factors and ...
Totò Schillaci, who passed away today, September 18, had been suffering from colon cancer for some time. His condition had ...
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback